Zevra Therapeutics, Inc. Costs and Expenses
Zevra Therapeutics, Inc. (ZVRA) reported Costs and Expenses of $21.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-05
- Zevra Therapeutics, Inc. costs and expenses for the quarter ending 2026-06-30 was $21.05M, a 13.09% decline year-over-year.
- Zevra Therapeutics, Inc. costs and expenses for the quarter ending 2026-03-31 was $25.18M, a 10.40% increase year-over-year.
- Zevra Therapeutics, Inc. costs and expenses for the quarter ending 2025-12-31 was $22.97M, a 6.14% decline year-over-year.
- Zevra Therapeutics, Inc. costs and expenses for the quarter ending 2025-09-30 was $20.37M, a 24.99% decline year-over-year.
- Zevra Therapeutics, Inc. costs and expenses for fiscal 2025 was $90.36M, a 6.81% decline from fiscal 2024.
- Zevra Therapeutics, Inc. costs and expenses for fiscal 2024 was $96.96M, a 30.82% increase from fiscal 2023.
- Zevra Therapeutics, Inc. costs and expenses for fiscal 2023 was $74.12M, a 40.58% increase from fiscal 2022.
- Zevra Therapeutics, Inc. costs and expenses for fiscal 2022 was $52.73M, a 152.02% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $21.05M 10-Q · filed 2026-08-05 | $46.22M 10-Q · filed 2026-08-05 | $69.19M derived: sum of 3 quarters · filed 2026-08-05 | $89.56M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $25.18M 10-Q · filed 2026-05-06 | $48.15M derived: sum of 2 quarters · filed 2026-05-06 | $68.52M derived: sum of 3 quarters · filed 2026-05-06 | $92.73M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $22.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $43.34M derived: sum of 2 quarters · filed 2026-03-09 | $67.56M derived: sum of 3 quarters · filed 2026-08-05 | $90.36M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $20.37M 10-Q · filed 2025-11-05 | $44.58M derived: sum of 2 quarters · filed 2026-08-05 | $67.39M 10-Q · filed 2025-11-05 | $91.86M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $24.21M 10-Q · filed 2026-08-05 | $47.02M 10-Q · filed 2026-08-05 | $71.50M derived: sum of 3 quarters · filed 2026-08-05 | $98.65M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $22.80M 10-Q · filed 2026-05-06 | $47.28M derived: sum of 2 quarters · filed 2026-05-06 | $74.43M derived: sum of 3 quarters · filed 2026-05-06 | $97.56M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $24.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $51.63M derived: sum of 2 quarters · filed 2026-03-09 | $74.75M derived: sum of 3 quarters · filed 2026-03-09 | $96.96M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $27.15M 10-Q · filed 2025-11-05 | $50.28M derived: sum of 2 quarters · filed 2025-11-05 | $72.49M 10-Q · filed 2025-11-05 | $98.56M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $23.13M 10-Q · filed 2025-08-12 | $45.33M 10-Q · filed 2025-08-12 | $71.41M derived: sum of 3 quarters · filed 2025-08-12 | $89.53M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $22.21M 10-Q · filed 2025-05-13 | $48.29M derived: sum of 2 quarters · filed 2025-05-13 | $66.40M derived: sum of 3 quarters · filed 2025-05-13 | $80.45M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $26.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $44.19M derived: sum of 2 quarters · filed 2025-03-12 | $58.24M derived: sum of 3 quarters · filed 2025-03-12 | $74.12M 10-K · filed 2025-03-12 | $77.06M 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $18.11M 10-Q · filed 2024-11-13 | $18.26M 10-Q · filed 2023-11-07 | $32.16M derived: sum of 2 quarters · filed 2024-11-13 | $48.04M 10-Q · filed 2024-11-13 | $49.18M 10-Q · filed 2023-11-07 | $59.38M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $14.04M 10-Q · filed 2024-08-14 | $15.12M 10-Q · filed 2023-08-14 | $29.93M 10-Q · filed 2024-08-14 | $30.92M 10-Q · filed 2023-08-14 | $41.26M derived: sum of 3 quarters · filed 2024-08-14 | $50.76M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $15.88M 10-Q · filed 2024-05-09 | $15.80M 10-Q · filed 2023-05-15 | $27.22M derived: sum of 2 quarters · filed 2024-05-09 | $36.72M derived: sum of 3 quarters · filed 2024-05-09 | $62.78M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $11.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $20.84M derived: sum of 2 quarters · filed 2024-04-01 | $46.90M derived: sum of 3 quarters · filed 2024-04-01 | $52.73M 10-K · filed 2024-04-01 | $52.96M 10-K · filed 2023-03-07 | |||
| 2022-09-30 | $9.50M 10-Q · filed 2023-11-07 | $35.57M derived: sum of 2 quarters · filed 2023-11-07 | $41.39M 10-Q · filed 2023-11-07 | $46.81M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $26.07M 10-Q · filed 2023-08-14 | $31.89M 10-Q · filed 2023-08-14 | $37.31M derived: sum of 3 quarters · filed 2023-08-14 | $41.50M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $5.82M 10-Q · filed 2023-05-15 | $11.25M derived: sum of 2 quarters · filed 2023-05-15 | $15.44M derived: sum of 3 quarters · filed 2023-05-15 | $21.59M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $9.61M derived: sum of 2 quarters · filed 2023-03-07 | $15.76M derived: sum of 3 quarters · filed 2023-03-07 | $20.92M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $4.19M 10-Q · filed 2022-11-10 | $10.34M derived: sum of 2 quarters · filed 2022-11-10 | $15.50M 10-Q · filed 2022-11-10 | $21.08M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $6.15M 10-Q · filed 2022-08-12 | $11.31M 10-Q · filed 2022-08-12 | $16.89M derived: sum of 3 quarters · filed 2022-08-12 | $20.03M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $5.16M 10-Q · filed 2022-05-12 | $10.74M derived: sum of 2 quarters · filed 2022-05-12 | $13.88M derived: sum of 3 quarters · filed 2022-05-12 | $18.19M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $8.72M derived: sum of 2 quarters · filed 2022-03-31 | $13.03M derived: sum of 3 quarters · filed 2022-03-31 | $18.90M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $3.14M 10-Q · filed 2021-11-10 | $7.45M derived: sum of 2 quarters · filed 2021-11-10 | $13.32M 10-Q · filed 2021-11-10 | $19.10M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $4.32M 10-Q · filed 2021-08-13 | $10.18M 10-Q · filed 2021-08-13 | $15.96M derived: sum of 3 quarters · filed 2021-08-13 | $24.19M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $5.86M 10-Q · filed 2021-05-14 | $11.65M derived: sum of 2 quarters · filed 2021-05-14 | $19.88M derived: sum of 3 quarters · filed 2021-05-14 | $27.67M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $14.02M derived: sum of 2 quarters · filed 2021-03-12 | $21.81M derived: sum of 3 quarters · filed 2021-03-12 | $33.18M 10-K · filed 2021-03-12 | ||||
| 2019-09-30 | $8.23M 10-Q · filed 2020-10-30 | $16.02M derived: sum of 2 quarters · filed 2020-10-30 | $27.39M 10-Q · filed 2020-10-30 | $36.66M derived: sum of 4 quarters · filed 2020-10-30 | ||||
| 2019-06-30 | $7.79M 10-Q · filed 2020-08-12 | $19.16M 10-Q · filed 2020-08-12 | $28.43M derived: sum of 3 quarters · filed 2020-08-12 | $46.39M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | $11.37M 10-Q · filed 2020-05-13 | $20.64M derived: sum of 2 quarters · filed 2020-05-13 | $38.59M derived: sum of 3 quarters · filed 2020-05-13 | |||||
| 2018-12-31 | $9.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $27.23M derived: sum of 2 quarters · filed 2020-02-28 | $55.90M 10-K · filed 2020-02-28 | |||||
| 2018-09-30 | $17.96M 10-Q · filed 2019-11-14 | $46.63M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |